UK Arrhythmia Alliance invites nominations for innovation awards:
This article was originally published in Clinica
The Arrhythmia Alliance, the influential UK pressure group in the areas of cardiac pacing/resynchronisation technology access and care policy, is inviting manufacturers to nominate for its 2007 "Excellence in Practice" awards. The awards will be made for three categories, covering: outstanding contributions to the development of arrhythmia services; innovations through research or training; and "innovations through service developments" that might serve as a model to other services. The closing date for nominations (online at www.heartrhythm.org.uk) is September 21.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.